| First Author | Zhu G | Year | 2021 |
| Journal | Nat Commun | Volume | 12 |
| Issue | 1 | Pages | 1956 |
| PubMed ID | 33782403 | Mgi Jnum | J:304846 |
| Mgi Id | MGI:6515284 | Doi | 10.1038/s41467-021-22095-2 |
| Citation | Zhu G, et al. (2021) HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. Nat Commun 12(1):1956 |
| abstractText | Nucleophosmin (NPM1) is the most commonly mutated gene in acute myeloid leukemia (AML) resulting in aberrant cytoplasmic translocation of the encoded nucleolar protein (NPM1c(+)). NPM1c(+) maintains a unique leukemic gene expression program, characterized by activation of HOXA/B clusters and MEIS1 oncogene to facilitate leukemogenesis. However, the mechanisms by which NPM1c(+) controls such gene expression patterns to promote leukemogenesis remain largely unknown. Here, we show that the activation of HOXBLINC, a HOXB locus-associated long non-coding RNA (lncRNA), is a critical downstream mediator of NPM1c(+)-associated leukemic transcription program and leukemogenesis. HOXBLINC loss attenuates NPM1c(+)-driven leukemogenesis by rectifying the signature of NPM1c(+) leukemic transcription programs. Furthermore, overexpression of HoxBlinc (HoxBlincTg) in mice enhances HSC self-renewal and expands myelopoiesis, leading to the development of AML-like disease, reminiscent of the phenotypes seen in the Npm1 mutant knock-in (Npm1(c/+)) mice. HoxBlincTg and Npm1(c/+) HSPCs share significantly overlapped transcriptome and chromatin structure. Mechanistically, HoxBlinc binds to the promoter regions of NPM1c(+) signature genes to control their activation in HoxBlincTg HSPCs, via MLL1 recruitment and promoter H3K4me3 modification. Our study reveals that HOXBLINC lncRNA activation plays an essential oncogenic role in NPM1c(+) leukemia. HOXBLINC and its partner MLL1 are potential therapeutic targets for NPM1c(+) AML. |
